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Brief Technique Reportsedges of the atriotomy, and the valve replacement was com-
pleted. After right atrial closure, the balloons were deflated,
and the catheters were withdrawn. The operation was con-
cluded in the standard fashion.
DISCUSSION
In our center a small right thoracotomy on the beating
heart is the preferred technique for patients undergoing
redo operations requiring a tricuspid or mitral valve opera-
tion. Excellent exposure is crucial for a successful valve
procedure, particularly when the operation is conducted
through small incisions. In addition, this approach offers
a good exposure to the atrial valves and minimizes the me-
diastinal dissection, playing a key role in reduction of blood
loss and cardiac injuries.4
The use of vacuuming without caval occlusion allows
a bloodless surgical field; however, air aspiration on venous
drainage can cause some problems in the extracorporeal cir-
culation. Our technique of caval occlusion represents a use-
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462 The Journal of Thoracic and Cardiovascular Surgwe have now used this approach only twice, we strongly
believe that it is attractive for several reasons. First of all,
it reduces mediastinal dissection and the relative risk of in-
juries to the great vessels. Moreover, it allows a bloodless
working environment. Last, but not least, the technique is
safe and easy to perform. We think that it should be kept
in the armamentarium of the cardiothoracic surgeon and
should be considered in all reoperative operations per-
formed with minithoracotomies.References
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complex reoperative mitral valve surgeryRobert Saeid Farivar, MD, PhD,a Seth Lowy, BS,b and Joss Fernandez, MD,a Iowa City, Iowa, and Irvine,
CalifA 54-year-old man had severe paravalvular leak 10 years
after a secondmitral valve replacement and thirdmitral valve
operation. As a child, the patient had a congenital partial
atrioventricular canal defect. He underwent patch repair of
the septum secundum atrial septal defect and had a cleft mi-
tral repair at age 16 years. This repair was durable until the
age of 28 years, when he required mitral valve replacement
with a 31-mmBj€ork–Shileymechanical valve (Shiley, Inc, Ir-
vine,Calif) for severemitral regurgitation.At 44 years of age,
although this valve was functioning well, he had it replaced
owing to failure risk. The patient underwent mitral valve
re-replacement with a 29-mm CarboMedics valve (SulzerCarboMedics, Inc, Austin, Tex) approximately 10 years
ago. During that operation, he had a perioperative stroke
and a 1-month hospital stay. Nonetheless, he made a full re-
covery and now returned for a fourth mitral valve procedure.
During the previous year, symptomatic severe mitral re-
gurgitation had developed. Echocardiography demon-
strated mitral regurgitation along a 160 dehiscence along
the previous P1–P2 region. The valve was not ‘‘rocking.’’
He had an 8-cm left atrium, normal left ventricular function,
along with mild aortic insufficiency and moderate tricuspid
regurgitation. Right heart catheterization demonstrated ele-
vated pulmonary pressures (55 mm Hg/21 mm Hg) and
a mean wedge pressure of 20 mm Hg. Comorbidities in-
cluded Childs–Pugh class A cirrhosis owing to long-
standing congestive hepatopathy and chronic obstructive
pulmonary disease on 2 L of supplemental oxygen.
Given the hostile mediastinum, the decision was made to
approach the mitral valve by a right thoracotomy. Evalua-
tion of the aortoiliac system with computed tomography
demonstrated severe disease. As a result, axillary cannula-
tion was chosen for antegrade flow. Given the aortic valve
insufficiency, we decided against cold fibrillatory arrest,
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FIGURE 1. A, Right anterolateral thoracotomy in the fourth intercostal space demonstrating an 8-mm Dacron graft (Ax) sewn to the axillary artery. The
endoballoon (Eb) is advanced through the side arm, which is attached to the Dacron graft. The final arm provides arterial inflow. B, Postoperative incision (14
days) documenting the axillary and inframammary and chest tubes incisions. C, Fluoroscopic shot demonstrating themultistage 25F femoral venous cannula
placed bicavally (Fv), the endopulmonary artery vent placed through the right internal jugular vein (Ev), the coronary sinus catheter (Csc) placed through the
right internal jugular vein as well. D, Angiographic subtracted film demonstrating the endoballoon (Eb) placed through the right axillary–innominate arterial
system, with the balloon at the sinotubular junction. The aortic valve has good competency and the great vessels are shown.
Brief Technique Reports(Edwards Lifesciences LLC, Irvine, Calif) was used with
modifications.
The patient was placed in a gentle right thoracotomy
position. Via the right internal jugular vein, an EndoVent
catheter (Edwards Lifesciences) was placed in the pulmo-
nary artery, and a coronary sinus catheter was placed for ret-
rograde cardioplegia before incision (Figure 1, C). We
exposed the right axillary artery in the deltopectoral groove
at the lateral third of the clavicle (Figure 1, A). We admin-
istered 5000 units of heparin and then attached an 8-mm
Dacron graft as a ‘‘chimney’’ in an end-to-side manner.
We then attached a 21-mm endocannula with a Y-arm for
an endoballoon and connector for antegrade perfusion
(Figure 1, A). We performed a thoracotomy in the right
fourth intercostal space in the inframammary crease. After
extensive adhesiolysis, we administered systemic heparin
and placed a 25F femoral venous cannula bicavally with
echocardiographic guidance (Figure 1, C).
Using fluoroscopy, we then placed a guidewire through
the axillary system abutting the aortic valve (Figure 1, D)
at the sinotubular junction.We then administered full bypass
in an antegrade manner via the axillary cannula (Figure 1,
D). We were able to achieve a flow rate of 5 L/min. UsingThe Journal of Thoracic and Camoderate hypothermia and antegrade (through the endobal-
loon) as well as retrograde (using the coronary sinus cathe-
ter) cardioplegia, we arrested the heart and then approached
the mitral valve.
We dissected out the Sondergaard groove inasmuch as
the patient had a previous transseptal patch from the cleft
mitral repair. We inflated the endoballoon to arrest the heart.
The previous valve was encountered in a severely enlarged
8-cm left atrium with an obvious, nearly 180 dehiscence
and fibrin across the valve. The patient underwent routine
third time mitral valve replacement with a size 29 tissue
valve. Total endoballoon (crossclamp) timewas 87minutes,
and bypass time was 160 minutes. He was discharged home
on postoperative day 16 in good condition. His recovery
was slowed owing to Childs–Pugh A cirrhosis. At 2 months’
follow-up, he is in excellent condition, no longer receiving
supplemental oxygen at home, and with decreasing furose-
mide (Lasix) requirement.
DISCUSSION
Minimally invasive and right chest approaches to the mi-
tral valve have been used for complex reoperative mitral
valve surgery as well as routine mitral valve surgery.1 Theyrdiovascular Surgery c Volume 142, Number 2 463
Brief Technique Reportsoffer advantages such as avoidance of a hostile mediastinum
with previous coronary bypass grafts and adhesed chambers.
In the case of endocannulae and endo-occlusion, they offer
the ability to perform the procedure with a single incision
on the heart. There are disadvantages, such as the need to dis-
sect out the aorta if a crossclamp is used and retrograde arte-
rial flow if the femoral system is used. Additionally, older
data with femoral access and endoballoon occlusion had
shown high dissection rates,2 although this has not been
the case in more modern series of port access surgery.3
In our case, because the patient had a previous stroke and
multiple previous procedures in a moderately calcified sys-
tem, we preferred antegrade flow and chose an axillary can-
nulation strategy. Additionally, inasmuch as we wished to
minimize dissection of the aorta from a right chest
approach, we chose to place the endoballoon through the
axillary chimney. This strategy yielded excellent flows of
up to 5 L/min when using vacuum-assisted drainage and
a 25F multilumen femoral venous cannula. Although we
could have chosen a cold fibrillatory strategy, the aortic in-
sufficiency and the need to remove a heavily entrenched
valve dissuaded us from that method. The combination ofFrom the Thessaloniki Heart Institute,a St Luke’s Hospital, Thessaloniki, Greece; and
the Second Department of Cardiology,b Medical School, University of Athens,
Attikon Hospital, Athens, Greece.
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464 The Journal of Thoracic and Cardiovascular Surgantegrade cardioplegia through the aortic root and intermit-
tent retrograde cardioplegia through the coronary sinus,
along with moderate (28C) hypothermia, provided excel-
lent protection during the right thoracotomy. Separation
from bypass was uneventful. Postoperatively, he continues
to do well and is pleased with the cosmetic aspect of the
scar as well (Figure 1, B).
To our knowledge, this is one of the few reports of axil-
lary cannulation with an endoballoon placed through the ax-
illary cannula. In our hands, it was a reasonable strategy for
complex reoperative mitral surgery and may be an interest-
ing method for providing antegrade flow and a single suture
line on the heart when performing mitral valve surgery.References
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2003;108(Suppl 1):II48-54.Total ventricular assist for long-term treatment of heart failureAntonis A. Pitsis, MD, FETCS, FESC,a Aikaterini N. Visouli, MD,a Vlasis Ninios, MD, MRCP,a and
Dimitrios T. Kremastinos, MD, FESC,b Thessaloniki and Athens, GreeceDespite expert opinion that mechanical circulatory sup-
port (MCS) should be considered before the sequelae of se-
vere right ventricular (RV) failure, biventricular support is
applied in a significant percentage of long-term MCS
recipients and is associated with increased mortality
compared with mortality after isolated left ventricular
(LV) support.1
Total artificial heart and biventricular MCS application
is closely related to transplant eligibility.2 Transplant-
ineligible patients with refractory biventricular failure have
no treatment options other than end-of-life care.Implantation of newer-generation, long-term, continuous-
flow left ventricular assist devices (LVADs) has contributed
to improved results of MCS.3 Long-term, continuous-flow,
right ventricular assist devices (RVADs) do not exist, and
long-term biventricular support with the new pumps has
not been reported.CLINICAL SUMMARY
We report the first cases of elective, single-stage, LV
and RV support with 2 second-generation axial flow pumps.
We applied total ventricular assist (tVA) as long-term treat-
ment to 2 male patients with ischemic and idiopathic
end-stage biventricular failure in Interagency Registry for
Mechanically Assisted Circulatory Support profiles 2 and
3. The patients were not suitable for transplantation because
of advanced age and diabetes mellitus with end-organ
damage; the second patient also had fixed pulmonary hyper-
tension, increased pulmonary vascular resistance, and
transpulmonary gradient (Table 1). Institutional ethics com-
mittee approval and informed consent were obtained in both
cases.ery c August 2011
